Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019432877> ?p ?o ?g. }
- W2019432877 endingPage "1456" @default.
- W2019432877 startingPage "1443" @default.
- W2019432877 abstract "Currently, there is no definitive diagnostic test for traumatic brain injury (TBI) to help physicians determine the seriousness of injury or the extent of cellular pathology. Calpain cleaves αII-spectrin into breakdown products (SBDP) after TBI and ischemia. Mean levels of both ipsilateral cortex (IC) and cerebral spinal fluid (CSF) SBDP at 2, 6, and 24 h after two levels of controlled cortical impact (1.0 mm and 1.6 mm of cortical deformation) in rats were significantly elevated by injury. CSF and IC SBDP levels were significantly higher after severe (1.6 mm) injury than mild (1.0 mm) injury over time. The correlation between CSF SBDP levels and lesion size from T2-weighted magnetic resonance images 24 hours after TBI as well as correlation of tau and S100β was assessed. Mean levels of CSF SBDP (r = 0.833) and tau (r = 0.693) significantly correlated with lesion size while levels of CSF S100β did not (r = 0.188). Although levels of CSF and IC SBDP and lesion size are all significantly higher after 1.6 mm than 1.0 mm injury, the correlation between CSF SBDP and lesion size was not significant following the removal of controls from the analysis. This indicates CSF SBDP is a reliable marker of the presence or absence of injury. Furthermore, larger lesion sizes 24 h after TBI were negatively correlated with motor performance on days 1–5 after TBI (r = –0.708). Based on these data, evaluation of CSF SBDP levels as a biomarker of TBI is warranted in clinical studies." @default.
- W2019432877 created "2016-06-24" @default.
- W2019432877 creator A5011539117 @default.
- W2019432877 creator A5029878395 @default.
- W2019432877 creator A5037707621 @default.
- W2019432877 creator A5055437280 @default.
- W2019432877 creator A5058608452 @default.
- W2019432877 creator A5059902188 @default.
- W2019432877 creator A5067454835 @default.
- W2019432877 creator A5084464733 @default.
- W2019432877 date "2004-10-01" @default.
- W2019432877 modified "2023-10-18" @default.
- W2019432877 title "A Novel Marker for Traumatic Brain Injury: CSF αII-Spectrin Breakdown Product Levels" @default.
- W2019432877 cites W1518531861 @default.
- W2019432877 cites W1539967852 @default.
- W2019432877 cites W1544685573 @default.
- W2019432877 cites W1580653784 @default.
- W2019432877 cites W1655344346 @default.
- W2019432877 cites W1820347542 @default.
- W2019432877 cites W1965364787 @default.
- W2019432877 cites W1966558330 @default.
- W2019432877 cites W1967138600 @default.
- W2019432877 cites W1969597070 @default.
- W2019432877 cites W1978208103 @default.
- W2019432877 cites W1979038718 @default.
- W2019432877 cites W1981209372 @default.
- W2019432877 cites W1983751530 @default.
- W2019432877 cites W1984305500 @default.
- W2019432877 cites W1992372295 @default.
- W2019432877 cites W2003409520 @default.
- W2019432877 cites W2004696798 @default.
- W2019432877 cites W2005190760 @default.
- W2019432877 cites W2008245435 @default.
- W2019432877 cites W2011526137 @default.
- W2019432877 cites W2012382378 @default.
- W2019432877 cites W2017426600 @default.
- W2019432877 cites W2020822328 @default.
- W2019432877 cites W2020997228 @default.
- W2019432877 cites W2023775209 @default.
- W2019432877 cites W2024746592 @default.
- W2019432877 cites W2029430119 @default.
- W2019432877 cites W2043674339 @default.
- W2019432877 cites W2046110964 @default.
- W2019432877 cites W2049875635 @default.
- W2019432877 cites W2053326225 @default.
- W2019432877 cites W2057714861 @default.
- W2019432877 cites W2062105641 @default.
- W2019432877 cites W2066330966 @default.
- W2019432877 cites W2067629356 @default.
- W2019432877 cites W2068149462 @default.
- W2019432877 cites W2071979043 @default.
- W2019432877 cites W2076825885 @default.
- W2019432877 cites W2076855848 @default.
- W2019432877 cites W2080695699 @default.
- W2019432877 cites W2085648215 @default.
- W2019432877 cites W2087071662 @default.
- W2019432877 cites W2089854608 @default.
- W2019432877 cites W2094720192 @default.
- W2019432877 cites W2098865977 @default.
- W2019432877 cites W2099492547 @default.
- W2019432877 cites W2113094956 @default.
- W2019432877 cites W2116032889 @default.
- W2019432877 cites W2122958546 @default.
- W2019432877 cites W2132866550 @default.
- W2019432877 cites W2136637949 @default.
- W2019432877 cites W2138069622 @default.
- W2019432877 cites W2140288128 @default.
- W2019432877 cites W2143117388 @default.
- W2019432877 cites W2149023741 @default.
- W2019432877 cites W2149538791 @default.
- W2019432877 cites W2151296105 @default.
- W2019432877 cites W2171390337 @default.
- W2019432877 cites W2327431438 @default.
- W2019432877 cites W2344992701 @default.
- W2019432877 cites W4251671944 @default.
- W2019432877 cites W4302924100 @default.
- W2019432877 cites W4362116953 @default.
- W2019432877 doi "https://doi.org/10.1089/neu.2004.21.1443" @default.
- W2019432877 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15672634" @default.
- W2019432877 hasPublicationYear "2004" @default.
- W2019432877 type Work @default.
- W2019432877 sameAs 2019432877 @default.
- W2019432877 citedByCount "117" @default.
- W2019432877 countsByYear W20194328772012 @default.
- W2019432877 countsByYear W20194328772013 @default.
- W2019432877 countsByYear W20194328772014 @default.
- W2019432877 countsByYear W20194328772015 @default.
- W2019432877 countsByYear W20194328772016 @default.
- W2019432877 countsByYear W20194328772017 @default.
- W2019432877 countsByYear W20194328772018 @default.
- W2019432877 countsByYear W20194328772019 @default.
- W2019432877 countsByYear W20194328772020 @default.
- W2019432877 countsByYear W20194328772021 @default.
- W2019432877 countsByYear W20194328772022 @default.
- W2019432877 countsByYear W20194328772023 @default.
- W2019432877 crossrefType "journal-article" @default.
- W2019432877 hasAuthorship W2019432877A5011539117 @default.
- W2019432877 hasAuthorship W2019432877A5029878395 @default.